Association Between miR-423 rs6505162 Polymorphism and Susceptibility to Cancer.
Alleles
Asian People
/ genetics
Breast Neoplasms
/ epidemiology
Case-Control Studies
Colorectal Neoplasms
/ epidemiology
Esophageal Neoplasms
/ epidemiology
Female
Genetic Predisposition to Disease
/ genetics
Humans
Lung Neoplasms
/ epidemiology
MicroRNAs
/ genetics
Odds Ratio
Polymorphism, Single Nucleotide
Risk
Cancer
Meta-analysis
Polymorphism
miR-423
rs6505162
Journal
Archives of medical research
ISSN: 1873-5487
Titre abrégé: Arch Med Res
Pays: United States
ID NLM: 9312706
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
09
10
2018
revised:
18
02
2019
accepted:
09
04
2019
entrez:
19
5
2019
pubmed:
19
5
2019
medline:
31
1
2020
Statut:
ppublish
Résumé
Previous studies investigated the impact of miR-423 rs6505162 C>A polymorphism on individual susceptibility to risk, but the conclusions are still controversial and inconclusive. We performed a meta-analysis to get a more precise and comprehensive assessment of the association between miR-423 rs6505162 variant and cancer risk. Relevant studies were identified by searching the PubMed, Web of Science, Scopus and Google scholar databases up to September 03, 2018. Twenty seven case-control studies comprising 10,500 cases and 13,781 controls were included. The strength of correlation between rs6505162 polymorphism and cancer risk was evaluated by odds ratios (ORs) and 95% confidence intervals (CIs) under six genetic models. The findings showed that rs6505162 variant significantly decreased the risk of cancer in heterozygous codominant (OR = 0.88, 95% CI = 0.79-0.97, p = 0.009, AC vs. CC), dominanat (OR = 0.86, 95% CI = 0.77-0.95, p = 0.005, AC + AA vs. CC), and allele (OR = 0.89, 95% CI = 0.82-0.96, p = 0.003, A vs. C) genetic models. Stratified analyses by cancer types revealed that rs6505162 variant significantly decreased the risk of gastrointestinal cancer, colorectal cancer and lung cancer. The variant was not associated with the risk of esophageal cancer, breast cancer and gastric cancer. In addition this variant was associated with protective effect against cancer in Asian population. In conclusion, the findings of this meta-analysis suggests that miR-423 rs6505162 polymorphism may play a role in protection against cancer. More well-designed studies are required to elucidate the exact role of miR-432 polymorphism on cancer development.
Sections du résumé
BACKGROUND AND AIMS
Previous studies investigated the impact of miR-423 rs6505162 C>A polymorphism on individual susceptibility to risk, but the conclusions are still controversial and inconclusive. We performed a meta-analysis to get a more precise and comprehensive assessment of the association between miR-423 rs6505162 variant and cancer risk.
METHODS
Relevant studies were identified by searching the PubMed, Web of Science, Scopus and Google scholar databases up to September 03, 2018. Twenty seven case-control studies comprising 10,500 cases and 13,781 controls were included. The strength of correlation between rs6505162 polymorphism and cancer risk was evaluated by odds ratios (ORs) and 95% confidence intervals (CIs) under six genetic models.
RESULTS
The findings showed that rs6505162 variant significantly decreased the risk of cancer in heterozygous codominant (OR = 0.88, 95% CI = 0.79-0.97, p = 0.009, AC vs. CC), dominanat (OR = 0.86, 95% CI = 0.77-0.95, p = 0.005, AC + AA vs. CC), and allele (OR = 0.89, 95% CI = 0.82-0.96, p = 0.003, A vs. C) genetic models. Stratified analyses by cancer types revealed that rs6505162 variant significantly decreased the risk of gastrointestinal cancer, colorectal cancer and lung cancer. The variant was not associated with the risk of esophageal cancer, breast cancer and gastric cancer. In addition this variant was associated with protective effect against cancer in Asian population.
CONCLUSION
In conclusion, the findings of this meta-analysis suggests that miR-423 rs6505162 polymorphism may play a role in protection against cancer. More well-designed studies are required to elucidate the exact role of miR-432 polymorphism on cancer development.
Identifiants
pubmed: 31101240
pii: S0188-4409(18)30658-1
doi: 10.1016/j.arcmed.2019.04.002
pii:
doi:
Substances chimiques
MIRN423 microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
21-30Informations de copyright
Copyright © 2019 IMSS. Published by Elsevier Inc. All rights reserved.